Generic vonoprazan put to the test against Brand-Name voquezna

NCT ID NCT07278349

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared a generic vonoprazan 20 mg tablet to the brand-name Voquezna in 28 healthy adults. Participants took a single dose of each under fasting conditions to see if the generic releases the same amount of drug into the bloodstream. The goal was to check bioequivalence, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vonoprazan

What this could lead to

If successful, this could help bring a lower-cost generic version of vonoprazan to market for treating stomach acid conditions.

What could go wrong

This is a small, early-phase study in healthy volunteers, not patients. It only checks if the drug levels match, not whether it actually treats disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophagitis gastritis Helicobacter pylori infectious disease peptic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IPRC International Pharmaceutical Research Center

    Amman, Sport City Circle, 11196, Jordan